Loading clinical trials...
Loading clinical trials...
An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Conditions
Interventions
BI 6727
Locations
2
Belgium
1230.1.32002 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1230.1.32001 Boehringer Ingelheim Investigational Site
Leuven, Belgium
Start Date
November 4, 2005
Primary Completion Date
January 19, 2009
Completion Date
April 6, 2021
Last Updated
October 3, 2023
NCT00026884
NCT07213804
NCT07159659
NCT07169851
NCT07191730
NCT06662786
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions